41 – 50 of 61
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Smoking as a risk factor for the radiological severity of rheumatoid arthritis: a study on six cohorts
(
- Contribution to journal › Article
-
Mark
Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis.
(
- Contribution to journal › Article
-
Mark
Efficacy and drug survival of anti-tumour necrosis factor-alpha therapies in patients with non-radiographic axial spondyloarthritis: an observational cohort study from Southern Sweden.
(
- Contribution to journal › Article
-
Mark
Further evidence for influenza and pneumococcal vaccination in patients treated with disease modifying antirheumatic drugs and anti-tumor necrosis factor agents.
(
- Contribution to journal › Debate/Note/Editorial
- 2013
-
Mark
Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis
(
- Contribution to journal › Article
-
Mark
Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs
(
- Contribution to journal › Article
- 2012
-
Mark
The effect of smoking and alcohol consumption on markers of systemic inflammation, immunoglobulin levels and immune response following pneumococcal vaccination in patients with arthritis
(
- Contribution to journal › Article
- 2011
-
Mark
Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors
(
- Contribution to journal › Article
-
Mark
Long-term mortality rate in rheumatoid arthritis patients with disease onset in the 1980s.
(
- Contribution to journal › Article
-
Mark
Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs.
(
- Contribution to journal › Article